indication

Metabolic Syndrome

Competitive landscape

as of 2026-07-01
Competitive set
6
5 approved · 1 pipeline

Projection timeline

actual past → guided future · protection walls overlaid
42 events
2020
2024
2028
2032
2036
2040
today
focal launch window
guided / estimated ↑
actual ↓
focal / guidedapprovallabel expansiontrial readoutcongressnclustered events (click to expand)guided (dashed = directional)competitor patent cliff

Competitive set

resolved drugs with trials in this indication
drugCompleted
Olanzapine
US-approved 1996 · ZYPREXA Intramuscular
Phase 44 trials
OwnerEli Lilly and Company
Protection2041
drugNot Yet Recruiting
Aripiprazole
US-approved 2002 · ABILIFY
Phase 43 trials
OwnerOtsuka Pharmaceutical Development & Commercialization, Inc.
Protection2041
drugCompleted
Risperidone
US-approved 1993 · RISPERDAL
Phase 43 trials
OwnerJanssen, L.P. - Investigator Initiated Studies Program
Protection2042
drugCompleted
Haloperidol
US-approved 1986 · Haldol Decanoate
—1 trial
OwnerJanssen, L.P. - Investigator Initiated Studies Program
Protection—
drugCompleted
Clozapine
US-approved 1989 · Clozaril
Phase 41 trial
OwnerShanghai Mental Health Center
Protection2028
drugCompleted
Flupentixol
Pipeline · Phase 4
Phase 41 trial
OwnerTechnical University of Munich
Protection—

Market size

prevalence as a range, not a number